Interventional equipment vendor C.R. Bard has invested $2 million for a minority equity interestin Diagnostic Ultrasound of Redmond, WA. Bard's patient care andurology divisions will also market Diagnostic Ultrasound's BladderScanBVI 2500 scanner in the
Interventional equipment vendor C.R. Bard has invested $2 million for a minority equity interestin Diagnostic Ultrasound of Redmond, WA. Bard's patient care andurology divisions will also market Diagnostic Ultrasound's BladderScanBVI 2500 scanner in the U.S.
BladderScan is a noninvasive, nonimaging ultrasound devicethat provides measurements of bladder volume. The measurementtechnique provides a lower cost and less risky alternative tourinary catheters often used for bladder diagnosis. Bard is amajor catheter supplier.
According to estimates from the Centers for Disease Control,the cost to the U.S. health-care system of hospital-induced infectionsamounts to over $2 billion annually. About 80% of these infectionsare induced during urinary catheterization.
Diagnostic Ultrasound expects sales to double this year, aidedby Bard's investment, the Bard marketing agreement, an equivalentinvestment by another unnamed source, and expanded internationalbusiness. The company's other product is Versadopp 10, a pen-sizedDoppler blood-flow sensor used to evaluate the risk of strokeor peripheral artery disease and to assist in surgery.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.